SUYAK-MORFOGENETIK OQSILI-7 – DIABETIK NEFROPATIYANING ERTA BELGISI
##article.subject##:
suyak-morfogenetik oqsili-7, qandli diabet, diabetik nefropatiya, ko’ptokchalar filtratsiyasi tezligi, surunkali buyrak kasalligi##article.abstract##
Diabetik nefropatiya - qandli diabetda buyrakning shikastlanishi, nodulyar va diffuz glomeruloskleroz bilan namoyon bo'ladi va terminal bosqichda surunkali buyrak etishmovchiligi [37]. Diabetik nefropatiya diabetning eng og'ir asoratlaridan biri bo'lib, buyrak etishmovchiligining so'nggi bosqichida nogironlik va o'limga olib keladi [34, 35]. Statistik ma'lumotlarga ko'ra, diabetik nefropatiya 1-tur qandli diabet bilan kasallanganlarning 20,1 foizida va 2-toifa diabet bilan kasallanganlarning 6,3 foizida uchraydi [31]. Ammo diabetik nefropatiya rivojlanishining asosiy patofizyologik mexanizmlari diabetning ikkala turida ham bir xil va o'ziga xos emas [37]. Bundan tashqari, diabetik nefropatiya 2-toifa diabet bilan og'rigan bemorlarning o'lim sabablari ro'yxatida saraton va yurak-qon tomir kasalliklaridan keyin uchinchi o'rinda turadi [31]. Bundan tashqari, qandli diabet bilan og'rigan bemorlarning 50-75 foizida o'lim sababi diabetik nefropatiyadir [13, 33, 40]. Qo'shma Shtatlar har yili 1-tur qandli diabet bilan kasallangan odamlarni davolash uchun 1,9 milliard dollar sarflaydi, 2-toifa diabet bilan kasallanganlar uchun esa 15 milliard dollarni tashkil qiladi. Amerika Qo'shma Shtatlari buyrak donorlari ma'lumotlari tizimi tomonidan taqdim etilgan statistik ma'lumotlarga ko'ra, 2010 yilda deyarli 520 240 kishi dializga muhtoj bo'lgan, ularning yarmi 2-tur qandli diabet bilan kasallangan [37].
Библиографические ссылки
Bondar, I. A., Klimontov, V. V., Parfentieva, E. M., Romanov, V. V., & Nadeev, A. P. (2012). URINARY EXCRETION OF PROFIBROTIC AND ANTIFIBROTIC GROWTH FACTORS IN TYPE 1 DIABETIC PATIENTS: THE RELATION WITH DIABETIC NEPHROPATHY. Terapevticheskii arkhiv, 84(6), 36-40. https://edgccjournal.org/0040-3660/article/view/31045
De Petris, L., Hruska, K. A., Chiechio, S., & Liapis, H. (2007). Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrology Dialysis Transplantation, 22(12), 3442-3450. https://academic.oup.com/ndt/article/22/12/3442/1918263
Dolan, V., Murphy, M., Sadlier, D., Lappin, D., Doran, P., Godson, C., ... & Brady, H. R. (2005). Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. American Journal of Kidney Diseases, 45(6), 1034-1039. https://www.sciencedirect.com/science/article/abs/pii/S0272638605004506
Esposito C., Parrilla B., De Mauri A. et al. Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. Kidney Int. 2005; 67 (6): 2143—2150. https://www.sciencedirect.com/science/article/pii/S0085253815507035
Ina K., Kitamura H., Tatsukawa Sh. Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy // Medical. Electron. Microscopy. – 2002. – 35. P.87 – 95. https://link.springer.com/article/10.1007/s007950200011
Li, R. X., Yiu, W. H., & Tang, S. C. (2015). Role of bone morphogenetic protein-7 in renal fibrosis. Frontiers in physiology, 6, 114. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2015.00114/full
Lund, R. J., Davies, M. R., & Hruska, K. A. (2002). Bone morphogenetic protein-7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Current opinion in nephrology and hypertension, 11(1), 31-36. https://journals.lww.com/co-nephrolhypertens/abstract/2002/01000/bone_morphogenetic_protein_7__an_anti_fibrotic.5.aspx
Lv, S., Liu, G., Sun, A., Wang, J., Cheng, J., Wang, W., ... & Guan, G. (2014). Mesenchymal stem cells ameliorate diabetic glomerular fibrosis in vivo and in vitro by inhibiting TGF-β signalling via secretion of bone morphogenetic protein 7. Diabetes and Vascular Disease Research, 11(4), 251-261. https://journals.sagepub.com/doi/full/10.1177/1479164114531300
Mathew, S., Davies, M., Lund, R., Saab, G., & Hruska, K. A. (2006). Function and effect of bone morphogenetic protein‐7 in kidney bone and the bone‐vascular links in chronic kidney disease. European journal of clinical investigation, 36, 43-50. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2362.2006.01663.x
Mizuno S., Nakamura T. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2004; 286 (1): F134—F143. https://journals.physiology.org/doi/full/10.1152/ajprenal.00199.2003
Nguyen, T. Q., & Goldschmeding, R. (2008). Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis?. Pharmaceutical research, 25, 2416-2426. https://link.springer.com/article/10.1007/s11095-008-9548-9
Perera, N., Ritchie, R. H., & Tate, M. (2019). The role of bone morphogenetic proteins in diabetic complications. ACS Pharmacology & Translational Science, 3(1), 11-20. https://pubs.acs.org/doi/abs/10.1021/acsptsci.9b00064
Reutens, A. T., Prentice, L., & Atkins, R. C. (2008). The epidemiology of diabetic kidney disease. The epidemiology of diabetes mellitus, 499-517. https://onlinelibrary.wiley.com/doi/book/10.1002/9780470779750#page=511
Song, S. H., Han, D., Park, K., Um, J. E., Kim, S., Ku, M., ... & Kim, H. S. (2023). Bone morphogenetic protein-7 attenuates pancreatic damage under diabetic conditions and prevents progression to diabetic nephropathy via inhibition of ferroptosis. Frontiers in Endocrinology, 14, 1172199. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1172199/full
Strutz F., Zeisberg M., Hemmerlein B. et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 2000; 57 (4): 1521—1538. https://www.sciencedirect.com/science/article/pii/S0085253815469029
Strutz F. The role of FGF-2 in renal fibrogenesis. Front. Biosci. (Schol. Ed.) 2009; 1 (1): 125—131. file:///D:/%D0%97%D0%B0%D0%B3%D1%80%D1%83%D0%B7%D0%BA%D0%B8/Scholar12%20(1).pdf
Sugimoto, H., Grahovac, G., Zeisberg, M., & Kalluri, R. (2007). Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes, 56(7), 1825-1833. https://diabetesjournals.org/diabetes/article/56/7/1825/12585/Renal-Fibrosis-and-Glomerulosclerosis-in-a-New
Tervaert, T. W. C., Mooyaart, A. L., Amann, K., Cohen, A. H., Cook, H. T., Drachenberg, C. B., ... & Bruijn, J. A. (2010). Pathologic classification of diabetic nephropathy. Journal of the American Society of Nephrology, 21(4), 556-563. https://journals.lww.com/jasn/fulltext/2010/04000/pathologic_classification_of_diabetic_nephropathy.7.aspx.
Wang, S., Chen, Q., Simon, T. C., Strebeck, F., Chaudhary, L., Morrissey, J., ... & Hruska, K. A. (2003). Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney international, 63(6), 2037-2049. https://www.sciencedirect.com/science/article/pii/S0085253815491215
Wang, S., de Caestecker, M., Kopp, J., Mitu, G., LaPage, J., & Hirschberg, R. (2006). Renal bone morphogenetic protein-7 protects against diabetic nephropathy. Journal of the American Society of Nephrology, 17(9), 2504-2512. https://journals.lww.com/jasn/fulltext/2006/09000/renal_bone_morphogenetic_protein_7_protects.21.aspx
Wang S. N., Lapage J., Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J. Am. Soc. Nephrol. 2001; 12 (11): 2392-2399. https://journals.lww.com/jasn/pages/default.aspx
Yeh C. H., Chang C. K., Cheng M. F. et al. Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats. Horm. Metab. Res. 2009; 41 (8): 605—611. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0029-1220736
Yeh, C. H., Chang, C. K., Cheng, K. C., Li, Y. X., Zhang, Y. W., & Cheng, J. T. (2011). Role of Bone Morphogenetic Proteins‐7 (BMP‐7) in the Renal Improvement Effect of DangGui (Angelica sinensis) in Type‐1 Diabetic Rats. Evidence‐Based Complementary and Alternative Medicine, 2011(1), 796723. https://onlinelibrary.wiley.com/doi/full/10.1155/2011/796723
Zhang, Q., Shi, Y., Wada, J., Malakauskas, S. M., Liu, M., Ren, Y., ... & Zhang, Y. (2010). In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PloS one, 5(7), e11709. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011709
Zhang, Y., & Zhang, Q. (2009). Bone morphogenetic protein-7 and Gremlin: New emerging therapeutic targets for diabetic nephropathy. Biochemical and biophysical research communications, 383(1), 1-3. https://www.sciencedirect.com/science/article/abs/pii/S0006291X0900566X
Баранов А.А., Намазова-Баранова Л.С., Ильин А.Г., Булгакова В.А., Антонова Е.В. Смирнов И.Е. Научные исследования в педиатрии: направления, достижения, перспективы. Российский педиатрический журнал, 2013, 5: 4-14. https://cyberleninka.ru/article/n/nauchnye-issledovaniya-v-pediatrii-napravleniya-dostizheniya-perspektivy
Бондарь И.А., Климонтов В.В. Ранние маркеры диабетической нефропатии. Клиническая нефрология. 2010; 2: 60-5. https://www.elibrary.ru/ip_restricted.asp?rpage=https%3A%2F%2Fwww%2Eelibrary%2Eru%2Fitem%2Easp%3Fid%3D15113843
Бурнашева, Е. В., Шатохин, Ю. В., Снежко, И. В., & Мацуга, А. А. (2018). Поражение почек при противоопухолевой терапии. Нефрология, 22(5), 17-24. https://cyberleninka.ru/article/n/porazhenie-pochek-pri-protivoopuholevoy-terapii
Дедов И.И., Кураева Т.Л. Петеркова В.А. Сахарный диабет у детей и подростков. М.: ГЭОТАР-Медиа: 2007. https://cyberleninka.ru/article/n/rezultaty-realizatsii-podprogrammy-saharnyy-diabet-federalnoy-tselevoy-programmy-preduprezhdenie-i-borba-s-sotsialno-znachimymi
Дедов, И. И., Шестакова, М. В., & Андреева, Е. Н. (2011). Сахарный диабет: диагностика, лечение, профилактика./Под ред. Дедова ИИ, Шестаковой МВ–М.: Издательство медицинское информационное агентство. https://www.elibrary.ru/ip_restricted.asp?rpage=https%3A%2F%2Fwww%2Eelibrary%2Eru%2Fitem%2Easp%3Fid%3D23394475
Жариков, А. Ю., & Щекочихина, Р. О. (2018). Диабетическая нефропатия. Современный взгляд на проблему. Бюллетень медицинской науки, (2 (10)), 24-31. https://cyberleninka.ru/article/n/diabeticheskaya-nefropatiya-sovremennyy-vzglyad-na-problemu
Зайцев, В. В., Карягина, А. С., & Лунин, В. Г. (2009). Костные морфогенетические белки (BMP): общая характеристика, перспективы клинического применения в травматологии и ортопедии. Вестник травматологии и ортопедии им. НН Приорова, 4, 79-84. http://fc2dbb94f6074c2.s.siteapi.org/docs/de1bb3ae8dbf2567ab4640b714c49a76c873cd25.pdf
Кисельникова, О. В. (2017). Прогнозирование и ранняя диагностика диабетической нефропатии у детей. Москва. https://fnkc.ru/fnkc/diss-sovet/dissday/kiselnikova/autoreferat.pdf
Серкина, А. Н. (2021). ВЛИЯНИЕ ВНУТРИВЕННОГО ВВЕДЕНИЯ СТВОЛОВЫХ КЛЕТОК НА ПОКАЗАТЕЛИ АНТИОКСИДАНТНОЙ СИСТЕМЫ ПОЧЕК КРЫС ПОСЛЕ НАНЕСЕНИЯ ДЕФЕКТА КОСТИ. Juvenis scientia, 7(1), 24-31. https://cyberleninka.ru/article/n/vliyanie-vnutrivennogo-vvedeniya-stvolovyh-kletok-na-pokazateli-antioksidantnoy-sistemy-pochek-krys-posle-naneseniya-defekta-kosti
Смирнов, И. Е., Кучеренко, А. Г., Смирнова, Г. И., & Бадалян, А. Р. (2015). Диабетическая нефропатия. Российский педиатрический журнал, 18(4), 43-50. https://cyberleninka.ru/article/n/diabeticheskaya-nefropatiya
Шамхалова, М. Ш., Курумова, К. О., & Шестакова, М. В. (2009). Факторы тубулоинтерстициального поражения почек при сахарном диабете. Сахарный диабет, (4), 61-65. https://cyberleninka.ru/article/n/faktory-tubulointerstitsialnogo-porazheniya-pochek-pri-saharnom-diabete
Шестакова, М. В., & Дедов, И. И. (2000). Диабетическая нефропатия. М.: Универсум Паблишинг. http://www.voed.ru/diabet_nefropat.pdf
Шестакова М.В. Сахарный диабет и хроническая болезнь почек: современная диагностика и лечение. Вестник РАМН. 2012; 1: 45-9 https://cyberleninka.ru/article/n/saharnyy-diabet-i-hronicheskaya-bolezn-pochek-sovremennaya-diagnostika-i-lechenie/viewer
Шестакова, М. В., Сунцов, Ю. И., & Дедов, И. И. (2001). Диабетическая нефропатия: состояние проблемы в мире и в России. Сахарный диабет, (3), 2-5. https://cyberleninka.ru/article/n/diabeticheskaya-nefropatiya-sostoyanie-problemy-v-mire-i-v-rossii/viewer
Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш., Дедов И.И. Диабетическая нефропатия: достижения в диагностике, профилактике, лечении. Сахарный диабет. 2005; 3: 22-4. https://cyberleninka.ru/article/n/diabeticheskaya-nefropatiya-dostizheniya-v-diagnostike-profilaktike-i-lechenii/viewer
